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I started my PhD on January of 2014 with the first edition of the LisbonBiomed PhD 
program. During the first two months, I had the chance to participate in the training 
module “Towards a creative and critical mind” developed specifically to the 
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different research groups at Instituto de Medicina Molecular (IMM) in which we were 
exposed to varied activities, such as seminars, talks given by inspiring figures, clinical 
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developed by the research groups that were interested in receiving a PhD student in 
their labs. I liked very much the work presented by Dr. Sónia Sá Santos entitled 
“beating the blood-brain barrier” where she presented a bit about the European 
Project PEP2BRAIN. I was fascinated with the work on the analgesic peptides 
developed by MCastanho team and then I decided to join the group to continue the 
work with the promising kyotorphin (KTP) derivatives. Although Professor Miguel 
Castanho had initially thought in a work related to Dengue virus, he supported my 
decision to work with the peptide KTP and its derivatives. Together, we have 
elaborated a project to better understand the routes and targets of KTP analogues.  
This project allowed me to collaborate with the immunoregulation laboratory in the 
Laboratório de Toxinologia Aplicada, led by Dr. Mônica Lopes-Ferreira, at Instituto 
Butantan, where I spent 12 months in total. 
My PhD work originated the following papers:  
I. Pharmacological potential of the endogenous dipeptide kyotorphin and 
selected derivatives. 
Perazzo J, Castanho M and Sá Santos S. 





II. Endothelium-mediated action of analogues of the endogenous neuropeptide 
kyotorphin (Tyrosil-arginine): mechanistic insights from permeation and effects 
on microcirculation. 
Perazzo J, Lopes-Ferreira M, Sá Santos S, Serrano I, Pinto A, Lima C, Badarjí E, 
Tavares I, Heras M, Conceição K and Castanho MARB. 
ACS Chem Neurosci (2016), 7(8):1130-40. DOI: 0.1021/acschemneuro.6b00099 
 
III. Neuropeptide kyotorphin impacts on lipopolysaccharide-induced 
glucocorticoid-mediated inflammatory response. A molecular link to 
nociception, neuroprotection, and anti-inflammatory action. 
Perazzo J, Lima C, Heras M, Badarjí E, Lopes-Ferreira M, Castanho MARB. 
ACS Chem Neurosci (2017), DOI: 10.1021/acschemneuro.7b00007. [Epub ahead 
of print] 
 
IV. Improvement of the pharmacological properties of amidated kyotorphin by 
means of iodination. 
Oliveira MC, Gano L, Santos I, Correia JDC, Serrano ID, Sá Santos S, Ribeiro M, 
Perazzo J, Tavares I, Heras M, Badarjí E and Castanho MA. 
MedChemComm (2016), volume 7, pages 906-913, DOI: 10.1039/c6md00028b. 
 
This thesis is written in a paper format and is divided into 5 sections. In the first section 
the reader can find a bibliographic revision about KTP and selected derivatives, mainly 
the ones designed and studied by us. Section 2 conjugates data obtained from 
permeability in vitro, analgesic tests and intravital microscopy of selected derivatives 
of amidated kyotorphin (KTP-NH2) to help us to understand how simple structural 
modifications can impact the biological activity of the peptide. KTP-NH2 is one of the 
most inexpensive and most interesting molecules developed by us. Therefore, we went 
a bit further to understand the mechanisms behind the analgesic and anti-
inflammatory properties of this KTP analogue. Our efforts to address these questions 
resulted in the paper presented in section 3. A brief motivation for articles 2 and 3 
were included at the beginning of sections 2 and 3, respectively. A general conclusion 
of the results is presented in section 4. 
In this dissertation, two distinct referencing methods were followed. The references 
cited along the thesis (excluding articles) are listed in section 5, sorted alphabetically 
by first author’s last name. Within each paper the format of the references cited 
comply with the guidelines defined by the respective journal and are listed in the end 
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HPLC – high performance liquid chromatography 
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IL-1 – interleukin-1 
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Vis – visible 
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O neuropéptido endógeno denominado quiotorfina (L-Tyr-L-Arg, KTP) tem 
demonstrado uma notável atividade analgésica, podendo ser até 4.2 vezes mais 
potente do que opióides endógenos quando administrados diretamente no cérebro, 
mas é ineficiente quando administrado sistemicamente. O nosso grupo tem 
desenvolvido e estudado vários análogos da quiotorfina, entre eles a quiotorfina-
amida (L-Tyr-L-Arg-NH2, KTP-NH2), que é analgésica, anti-inflamatória e neuroprotetora 
após administração sistémica. Apesar deste conjunto interessante de propriedades 
biológicas, que tornam a KTP-NH2 um candidato interessante para desenvolvimento 
farmacológico, o desconhecimento do seu mecanismo de ação torna-se muito 
limitativo. É necessário progredir no avanço do entendimento das suas bases 
moleculares de ação para conseguir depois executar um plano de desenvolvimento 
industrial do fármaco. Este avanço passa por conseguir uma melhor compreensão da 
relação estrutura-função, estrutura-eficácia e estrutura-farmacocinética do fármaco, 
bem como revelar e caracterizar os seus alvos. 
O objetivo desta tese é contribuir para compreender os alvos e mecanismos de ação 
da KTP-NH2. Para alcançar esse objetivo, desenvolveram-se derivados da KTP-NH2 que 
contribuíram para elucidar novos aspetos da relação estrutura-atividade; e 
procuraram-se alvos específicos que pudessem explicar as atividades biológicas da 
KTP-NH2.  
Primeiro, introduziram-se pequenas alterações seletivas na estrutura química da KTP-
NH2 através da introdução de D-aminoácidos e/ou metilação N-terminal, de modo a 
aumentar a lipofilicidade e resistência à degradação enzimática. Observou-se que o 
péptido D-Tyr-L-Arg-NH2 (KTP-NH2-DL) tem um efeito anti-inflamatório pronunciado 
mas apresenta uma baixa atividade analgésica, provavelmente devido à baixa 
permeabilidade em membranas lipídicas. A KTP-NH2 apresenta um comportamento 
semelhante, exceto pela sua potente ação analgésica em vários modelos de dor. Estes 
resultados suportam a hipótese de que a KTP-NH2 utiliza transportadores específicos 




capazes de transportar os seus análogos, como a KTP-NH2-DL. Os isómeros metilados, 
quer seja em conformação LL ou LD, são bastante permeáveis em membranas lipídicas 
e provavelmente atravessam passivamente a barreira hematoencefálica. Este 
resultado, provavelmente associado a uma maior resistência à digestão enzimática, 
contribui para explicar o efeito analgésico prolongado desses derivados em 
comparação a KTP-NH2. No entanto, os isómeros metilados (LL e LD) têm atividade 
pró-inflamatória, o que lhes retira potencial farmacológico.  
Numa segunda fase, na tentativa de elucidar os mecanismos moleculares por detrás da 
ação da KTP-NH2, utilizou-se uma abordagem baseada em microscopia intravital e 
inibidores farmacológicos. Demonstrou-se que o KTP-NH2 é capaz de diminuir, em 
apenas 10 minutos, o número de leucócitos rolantes induzidos por lipopolissacáridos 
(LPS) ou CXCL-1, sugerindo um mecanismo de ação não genómico. No modelo de 
inflamação induzido por LPS, a KTP-NH2 não conseguiu diminuir o número de 
leucócitos rolantes em ratinhos pré-tratados com metirapone, um inibidor da síntese 
de glucocorticóides (GCs), ou com um inibidor do receptor de interleucina-1. Além 
disso, o mesmo dipéptido não foi tão eficaz na redução do número de leucócitos 
rolantes em ratinhos estimulados com LPS e pré-tratados com um inibidor de heme-
oxigenase-1 ou com um inibidor de interleucina-10. O pré-tratamento dos animais 
estimulados com LPS com um inibidor de MyD88 não afectou a ação da KTP-NH2. No 
modelo de inflamação induzido com CXCL-1, o pré-tratamento com metirapone não 
afectou a ação anti-inflamatória da KTP-NH2. Assim, concluiu-se que a KTP-NH2 tem 
dupla ação: uma ação mediada por GCs, que é dominante em modelos de inflamação 
completos, e um mecanismo independente de GCs, que é predominante em modelos 
em que o rolamento de leucócitos é estimulado, mas a inflamação não está totalmente 
desenvolvida. Testou-se também a hipótese da KTP-NH2 ser um inibidor de 
encefalinases. Ao contrário do dipeptídeo endógeno KTP, a KTP-NH2 não inibiu a 
enzima conversora da angiotensina (ECA) nem a dipeptidil-peptidase III (DPP3). 
Contudo, não descartamos a possibilidade da KTP-NH2 poder inibir outras 
encefalinases não testadas.  
O trabalho nesta tese sugere que KTP-NH2 é um péptido multifuncional que tem ações 
tanto a nível central como periférico. A KTP-NH2 apresenta um mecanismo anti-
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inflamatório muito rápido (10 minutos) que bloqueia a expressão/ativação de 
moléculas de adesão no endotélio e propõe-se que os GCs sejam o elo molecular que 





The endogenous neuropeptide kyotorphin (L-Tyr-L-Arg, KTP) has remarkable analgesic 
activity, up to 4.2 fold more potent than endogenous opioids when administered 
directly into the brain, but is inefficient after systemic administration. Our group has 
designed and studied several KTP analogues, among them KTP-amide (L-Tyr-L-Arg-NH2, 
KTP-NH2), which is analgesic, anti-inflammatory and neuroprotective after systemic 
administration. Despite this interesting set of biological properties, what makes of KTP-
NH2 an interesting candidate for pharmacological development, the lack of knowledge 
on its mechanism of action is limiting. We need to improve our knowledge on the 
molecular basis of action of the peptide so then we can execute an industrial 
development plan for the drug. Understanding the relationships between the structure 
of the drug and its function, efficacy and pharmacokinetics as well as the identification 
and characterization of molecular targets will contribute to progress in that area. 
The aim of this thesis is contribute to understand the mechanism of action of KTP-NH2 
and to identify molecular targets of this peptide. To achieve such aim, we have 
designed and studied KTP-NH2 derivatives to elucidate new aspects of the structure-
activity relationship; and we looked for specific targets that could explain KTP-NH2 
biological activities. 
First, we introduced selective changes in the chemical structure of KTP-NH2 by 
introducing D-amino acids residues and/or N-terminal methylation, in order to 
improve lipophilicity and resistance to enzymatic degradation. We found that D-Tyr-L-
Arg-NH2 (KTP-NH2-DL) has a pronounced anti-inflammatory effect, but insignificant 
analgesic action probably due to its low permeation through lipid membranes. KTP-
NH2 has a similar behavior, except for its potent analgesic action in several pain 
models. The results support the hypothesis that KTP-NH2 uses a specific transporter to 
cross the blood-brain barrier (BBB), which is not efficient to transport KTP-NH2 
analogues. Methylated KTP-NH2 isomers, LL and LD, are very permeable through lipid 
membranes and probably diffuse passively across the BBB. They are also more 




in comparison with KTP-NH2, but the pro-inflammatory activity jeopardizes their 
pharmacological potential. 
In a second phase, to elucidate the mechanism of action of KTP-NH2 at the molecular 
level, we used an approach based on intravital microscopy (IVM) and pharmacological 
inhibitors. We have demonstrated that KTP-NH2 is able to decrease, within 10 minutes, 
the number of rolling leukocytes induced either by lipopolysaccharide (LPS) or CXCL-1, 
suggesting a nongenomic mechanism of action. In the inflammation model induced by 
LPS, KTP-NH2 failed to decrease the number of rolling leukocytes in mice pre-treated 
either with metyrapone, an inhibitor of glucocorticoid (GC) synthesis, or with an 
inhibitor of interleukin-1 receptor (IL-1R). In addition, KTP-NH2 was not as effective 
reducing the number of rolling leukocytes of LPS-stimulated mice pre-treated with an 
inhibitor of heme-oxygenase-1 (HO-1) or with an inhibitor of interleukin-10 (IL-10), but 
pre-treatment of the LPS-stimulated animals with an inhibitor of MyD88 did not affect 
the action of KTP-NH2. In the inflammation model induced with CXCL-1, pre-treatment 
with metyrapone did not affect the anti-inflammatory action of KTP-NH2. Thus, we 
concluded that KTP-NH2 has dual action: a GC-mediated action, which is dominant in 
full-fledged inflammation models, and a GC-independent mechanism, which is 
predominant in models in which leukocyte rolling is stimulated but inflammation is not 
totally developed. We also tested the hypothesis that KTP-NH2 could act as an inhibitor 
of enkephalinases. Unlike the endogenous dipeptide KTP, KTP-NH2 did not inhibit 
angiotensin-converting enzyme (ACE) neither dipeptidyl-peptidase III (DPP3). However, 
we do not rule out the possibility that KTP-NH2 can inhibit other untested 
enkephalinases.  
The work in this thesis suggests that KTP-NH2 is a multifunctional peptide that has both 
central and peripheral actions. KTP-NH2 presents a very fast (10 minutes) anti-
inflammatory mechanism that blocks the expression/activation of adhesion molecules 
on the endothelium and we propose that GCs might be the molecular link to explain 
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Kyotorphin: context and motivation 
The endogenous neuropeptide composed by the amino acids L-tyrosine (L-Tyr) and L-
arginine (L-Arg) was first isolated from bovine brain in 1979 and found later on in the 
brains of mice and rats, guinea pigs, squirrels and in human cerebrospinal fluid (CSF) 
(Takagi et al. 1979; Ueda et al. 1980; Nishimura et al. 1991; Santos et al. 2013). The 
dipeptide with morphine-like properties discovered in Kyoto was named kyotorphin 
(KTP) (Takagi et al. 1979). 
If centrally administered, KTP shows a naloxone-reversible analgesic activity up to 4.2 
times more potent than endogenous opioids (Takagi et al. 1979). However, KTP does 
not bind directly to opioid receptors (Takagi et al. 1979; Rackham et al. 1982). The 
opioid-dependent analgesic mechanism of action of KTP is mediated by the release of 
met-enkephalins and β-endorphins, which in turn activates δ- and/or µ-opioid 
receptors (Takagi et al. 1979; Shiomi et al. 1981; Rackham et al. 1982; Takagi et al. 
1982; Janicki and Lipkowski 1983). The exact mechanism of action of KTP is not totally 
understood. Some authors suggest that KTP suffers a rapid degradation, originating L-
Arg, a well-known substrate for nitric oxide synthase (NOS) (Kawabata et al. 1993; 
Kawabata et al. 1994). This would induce the production of nitric oxide (NO) and 
consequently the release of met-enkephalins. Other authors suggest that KTP induces 
met-enkephalin release after binding its receptor (Ueda et al. 1989; Ueda and Inoue 
2000). Specific binding assays using radioactive KTP reveal the presence of a specific 
receptor to KTP functionally coupled to phospholipase C (PLC) through G-protein (Ueda 
et al. 1989). However, the putative KTP receptor (KTPr) has never been identified. In 
addition, there are evidences that KTP can protect met-enkephalins from degradation 
by inhibiting enkephalinases (Takagi et al. 1979; Hazato et al. 1986; Miguel et al. 2007).  
Fifty percent of the total KTP found in the brain is concentrated in the cerebral cortex, 
a region with low content of opioid receptors and enkephalinases (Ueda et al. 1980). In 
addition to the unequal distribution of the peptide into the brain, several other 
naloxone-irreversible activities of KTP were reported (Sakurada et al. 1983; Inoue et al. 




opioid mechanism of action. The activity of KTP synthase was detected outside the 
central nervous system (CNS), in adrenal glands (Kawabata et al. 1996). Hereupon, it is 
reasonable to expect that KTP would also have peripheric activities. Pre-treatment 
with KTP, administered via intraplantar (i.pl.), inhibited the nociception caused by 
bradykinin (BK) in a peripheral pain reflex test (Inoue et al. 1997). The analgesic effect 
of KTP was completely abolished by leucine-arginine, an antagonist of KTPr, but was 
not affected by naloxone (Inoue et al. 1997). These data indicate that KTP blocked 
nociception in peripheral tissues through its binding to KTPr by an opioid-independent 
mechanism. KTP also plays a role in different physiological activities such as behavior 
modulator (Kolaeva et al. 2000), thermoregulatory (Sakurada et al. 1983), antiepileptic 
(Godlevsky et al. 1995), among others (Ignat'ev et al. 1998; Summy-Long et al. 1998). 
These activities are also not mediated by an opioid mechanism. For instance, the 
involvement of the thyrotropin-releasing hormone (TRH) neural system has been 
proposed instead of the opioid system to explain the role of KTP in thermoregulation 
(Sakurada et al. 1983), but little is known about the non-opioid mechanism of action 
on KTP.  
Recently, our group have established a link between pain, Alzheimer disease (AD) and 
KTP. Pain is underestimated in AD patients due to the cognitive impairment; and these 
patients have decreased level of KTP in the CSF. Moreover, the level of KTP in the CSF 
correlated inversely with the phosphorylated-tau protein (p-tau) in AD patients (Santos 
et al. 2013). P-tau is released as consequence of neuronal cell destruction and 
therefore constitutes a biomarker of AD disease. Our group have proposed KTP as a 
biomarker of AD that could also be used to evaluate pain in patients with cognitive 
impairment (Santos et al. 2013). 
KTP has shown a wide range of physiological activities, but the analgesic activity is by 
far the most studied. However, after systemic administration, KTP shows only a brief 
analgesic activity at high doses (Chen et al. 1998). The pharmacological potential of 
KTP is limited due to its inability of the peptide to cross the blood-brain barrier (BBB) 
and due to its susceptibility to enzymatic degradation (Chen et al. 1998). More 
recently, it has been proposed that the peptide could also be pumped out from the 
brain through efflux pumps (Jiang et al. 2009; Serrano et al. 2014; Serrano et al. 2015). 
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Peptide transporter 2 (PEPT2) is the proposed candidate. Within the brain, PEPT2 is 
expressed in astrocytes, ependymal cells and also in the apical membrane of choroid 
plexus (Berger and Hediger 1999; Dieck et al. 1999). The biodistribution of the 
transporter within the brain support the hypothesis that PEPT2 is implicated in the 
elimination of the peptide from the synapses and from the brain. The interaction 
between KTP and PEPT2 have been reported by different authors and methods (Fujita 
et al. 1999; Thakkar et al. 2008). More importantly, KTP showed enhanced analgesic 
response in PEPT2 null mice (Jiang et al. 2009). 
Kyotorphin Derivatives 
In 2009, our group joined a partnership with 2 other Universities and 2 companies in a 
project called PEP2BRAIN. The project aimed to develop safe KTP derivatives with 
analgesic efficacy, improved stability and ability to cross the BBB.  
C-terminal amidation and/or the addition of lipophilic groups to the N-terminal were 
some of the strategies applied to improve the formal net charge of the peptides or to 
increase lipophilicity, respectively. These strategies resulted in the creation of the 
following peptides (Figure 1). 
 
Figure 1. Kyotorphin (KTP), ibuprofen-KTP (IbKTP), ibuprofen-KTP-amide (IbKTP-NH2) 










Kyotorphin-amide (KTP-NH2) has been extensively studied in several acute and chronic 
pain models after systemic administration. At a dosage of 32.3 mg.kg-1, KTP-NH2 
showed an effect comparable to morphine at 5 mg.kg-1 in acute pain models, meaning 
the equi-effective dose of KTP-NH2 was about five fold that of morphine (Ribeiro et al. 
2011). In chronic pain models antinociception induced by KTP-NH2 was observed only 
after a week of daily treatment with 32.3mg.kg-1 and unlike morphine, the peptide did 
not show tolerance effects (Ribeiro et al. 2011). The analgesic effect of KTP-NH2 was 
reversed by naloxone but KTP-NH2 showed low affinity to opioid receptors (Ribeiro et 
al. 2011). In addition, it was demonstrated that nociceptive activation of spinal 
neurons induced by formalin was inhibited by systemic administration of KTP-NH2, as 
indicated by the lower number of Fos-immunoreactive neurons at the spinal dorsal 
horn (Ribeiro et al. 2011). This is a proof that KTP-NH2 can block nociceptive 
transmission in the CNS after systemic administration. Nonetheless, biodistribution 
studies are needed to follow the biological fate of the peptide in vivo, after systemic 
administration. 
The analgesic efficacy of KTP-NH2 was reasonable, albeit not optimal. Chemical 
conjugation of KTP and KTP-NH2 to the nonsteroidal anti-inflammatory drug ibuprofen 
(Ib) enhanced the analgesic activity of the peptide (Ribeiro et al. 2011). Naloxone 
decreased but did not completely abrogated the analgesic effect of IbKTP-NH2 (Ribeiro 
et al. 2011). IbKTP-NH2 also decreased the number of Fos-immunoreactive neurons 
providing an evidence for its central action (Ribeiro et al. 2011). The selectivity of 
IbKTP-NH2 to brain endothelial cells supports the hypothesis that grafting Ib to KTP-
NH2 enhances BBB crossing (Ribeiro et al. 2011). 
KTP-NH2 and IbKTP-NH2 have low affinity to opioid receptors, but their naloxone 
reversible effect suggests that they act, at least in part, by an indirect opioid 
mechanism (Ribeiro et al. 2011; Ribeiro et al. 2011). Despite the analgesic activity of 
KTP-NH2 and IbKTP-NH2 could be comparable to morphine, they do not have the major 
side effects associated to opioids such as constipation, increase in the blood pressure 
or food and water intake (Ribeiro et al. 2013). Both peptides have indeed a very safe 
profile. There are no evidences of in vitro cytotoxicity or hepatic lesions at effective 
doses (Ribeiro et al. 2013). KTP-NH2 only showed a reduction in micturition and IbKTP-
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NH2 showed a moderate locomotion decline in rats (Ribeiro et al. 2013). Overall, these 
peptides might constitute advantageous alternatives over opioids.  
Pain and inflammation are distinct physiological events, but they frequently coexist. 
The Ib moiety has previously shown to enhance KTP-NH2 analgesic activity. Similarly, 
KTP-NH2 was tested as an enhancer of Ib anti-inflammatory action. Using an intravital 
microscopy (IVM) approach it was demonstrated that KTP-NH2, IbKTP and IbKTP-NH2 
did not cause damage in the microcirculation (Conceição et al. 2016). In addition, they 
were able to decrease the number of rolling leukocytes induced by lipopolysaccharide 
(LPS). Isothermal titration calorimetry studies showed that the peptides can bind to 
LPS, probably hampering its binding to Toll-like receptor 4 (TLR4) and jeopardizing 
signal transduction that triggers leukocyte rolling and recruitment to peripheral tissues 
(Conceição et al. 2016). 
Recently, KTP-NH2 and IbKTP-NH2 have given proofs of their neuroprotective potential 
by improving cognitive deficits and preventing neuronal damage in a cerebral 
hypoperfusion dementia model (Sa Santos et al. 2016). 
In contrast to the abundant data on the biological action of these peptides, little effort 
has been made to unravel their mechanism of action. KPT-NH2 and IbKTP-NH2 are 
promising compounds for future pharmaceutical development, but the 
pharmacodynamic of these drugs still is a major concern. Several other analogues were 
synthesized and tested for their potential to transverse lipid membranes in vitro, as 
well as for their analgesic efficacy in vivo. The structural modifications consisted in the 
addition of different groups at the N-terminus, such as tert-butyloxycarbonyl (Boc), -
aminobutyric acid (GABA), acetyl, butanoyl and propanoyl or in the substitution of the 
tyrosine residue by an indole moiety (Serrano et al. 2015). In some cases, the peptide 
bond was replaced by a urea-like bond. This study was done with eight novel 
analogues and the results revealed that there was a correlation between analgesic 
efficacy and relative permeability, i.e. drugs with higher relative permeability (PR) 
across lipid membranes had a higher analgesic effect at 30 minutes in the hot plate 
test (Serrano et al. 2015). KTP and KTP-NH2 were exceptions to this correlation. While 




higher analgesic effect (Serrano et al. 2015). To explain these observations, the authors 
proposed that KTP might be pumped out from the brain by efflux pumps and KTP-NH2 
probably depended on a dipeptide transporter to translocate the BBB (Serrano et al. 
2015). Most of the structural modifications resulted in drugs with a more enduring 
analgesic effect than KTP-NH2, but we should be aware that the toxicity of these 
compounds has not been tested yet.  
KTP-NH2 gathers an interesting set of biological properties that makes of it an 
interesting candidate for pharmacological development, but the lack of knowledge on 
its mechanism of action is limiting. We need to improve our knowledge on the 
molecular basis of action of the peptide so then we can execute an industrial 
development plan for the drug. Understanding the relationships between the structure 
of the drug and its function, efficacy and pharmacokinetics as well as the identification 
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KTP-NH2 is a very interesting candidate for pharmacological development due to its 
biological activity, but the pharmacodynamics of the peptide still needs improvement. 
We first aim to introduce minor changes in the chemical structure of KTP-NH2 to 
optimize pharmacological action. Hopefully, these small chemical modifications will 
allow us to establish structure-activity relationships to understand how 
pharmacophores impact the stability and activity of the peptide. The stability of the 
analogues will be assayed in human serum and the ability to translocate the BBB will 
be evaluated in vitro using lipid membranes. We will focus on the analgesic and anti-
inflammatory activities of the peptides that will be quantified through the hot plate 
test and IVM parameters, respectively. In addition, IVM will allow the observation of 
potential damage caused by the peptides on microcirculatory environment.  
The mechanism of action of KTP-NH2 is an extremely important issue to be addressed. 
We hypothesize that the anti-inflammatory activity of KTP-NH2 could be the key to link 
analgesia and neuroprotection. We will resort to IVM again to explore the anti-
inflammatory mechanism of KTP-NH2. We will conjugate this technique with the use of 
pharmacological inhibitors of potential targets.  
It has been proposed that KTP could act as an inhibitor of enkephalinases, therefore 
extending the half-life of endogenous opioid peptides and inducing analgesia. KTP-NH2 
differs from KTP by amidation only. We will test the hypothesis that KTP-NH2 could 
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KTP-NH2 has given proof of its diversified biological activities as analgesic (Ribeiro et al. 
2011), anti-inflammatory (Conceição et al. 2016), antimicrobial (Ribeiro et al. 2012) 
and neuroprotector peptide (Sá Santos et al. 2016). However, the pharmacodynamics 
and pharmacokinetics of the dipeptide are not optimal and must be improved 
envisioning its pharmacological development (see appendix 1). In the work to be 
presented in this section, we designed KTP-NH2 derivatives introducing minor changes 
in the chemical structure, such as N-terminal methylation and/or use o D-amino acid 
residues to improve lipophilicity and resistance to enzymatic degradation. For the sake 
of 3R’s policy, only the most stable derivatives, with less than 10% conversion into free 
amino acids after 60 min by high performance liquid chromatography (HPLC) in human 
serum, were selected to be tested in vivo. 
Our approach consisted in first to analyze the impact of these derivatives on 
microcirculation using IVM. This technique brings the advantage of allowing 
observation and registration of the microcirculation in vivo and in real time in a simple 
and fast way. This technique is commonly used to evaluate the effects of substances 
such as peptides and proteins in microcirculation and muscle fibers. Different events 
can be observed at the same time, such as bleeding, thrombus formation, arteriolar 
contraction/expansion, leukocyte rolling, adhesion and transmigration, etc. For these 
reasons, this tool is very adequate to study the inflammatory processes. 
We have also tested the analgesic potential of these derivatives using the hot plate 
test and compared this data with the PR of these compounds. Our group had 
previously established a correlation between PR and analgesia, which applies to the 
majority of KTP derivatives tested (Serrano et al. 2015). However, KTP-NH2 is one of 
the exceptions. This peptide is not very efficient in translocating lipid membranes 
(Serrano et al. 2015). In fact, its PR is comparable to KTP, nevertheless KTP-NH2 
presents a remarkable analgesic activity after systemic administration in several pain 
models (Ribeiro et al. 2011).  
Interestingly, KTP-NH2 isomer, KTP-NH2-DL (D-Tyr-L-Arg-NH2) did not present a 
significant analgesic activity in the hot plate test. This data support the hypothesis that 




derivatives. Methylated derivatives are very permeable through lipid membranes and 
may diffuse passively across BBB. This is in accordance with the prolonged analgesic 
effect observed, which contrasts with KTP-NH2: maximal effect at 15 min and then 
decay over time (Ribeiro et al. 2011). 
KTP-NH2-DL has a pronounced anti-inflammatory action, similar to KTP-NH2, while 
methylation at the N-terminus results in a pro-inflammatory activity. The mechanisms 
of these drugs are not totally clear, but they clearly target the endothelium. 
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Article 2 demonstrated the endothelium-mediated action of the analogues of KTP. The 
methylated derivatives presented a prolonged analgesic effect, but they have a pro-
inflammatory action; KTP-NH2-DL was anti-inflammatory, but did not show a relevant 
analgesic activity. Despite KTP-NH2 analogues were more stable in human serum, KTP-
NH2 was the only one that gathered analgesic and anti-inflammatory activities 
simultaneously. Therefore, we selected KTP-NH2 to study further. The aim of the 
following paper was to shed light on the analgesic and anti-inflammatory mechanism 
of action of KTP-NH2 and to find the molecular link that might explain these effects.  
KTP-NH2 differs from KTP by substitution of the carboxylic acid for an amide. It is 
known that KTP has a naloxone-reversible analgesic effect 4.2 times more potent than 
met-enkephalins when administered directly into the brain (Takagi et al. 1979) but 
does not bind to opioid receptors (Takagi et al. 1979; Rackham et al. 1982; Ribeiro et 
al. 2011). Although the mechanism of action of KTP is not completely understood and 
some data are controversial, it is believed that KTP has the ability to induce the release 
of a particular type of opioid peptides, met-enkephalins, and stabilize their effect by 
inhibiting enkephalinases (Takagi et al. 1979; Shiomi et al. 1981; Janicki and Lipkowski 
1983; Hazato et al. 1986). Based on that, we raised the hypothesis that KTP-NH2 might 
also act as inhibitor of enkephalinases.  
Searching through the literature at least eight different human enkephalinases (Table 
1) are identified, most of them present in the brain. In this work, we tested the ability 
of KTP-NH2 to inhibit two enkephalinases, dypeptidyl-peptidase III (DPP3, EC 3.4.14.4) 
and angiotensin converting enzyme (ACE, EC 3.4.15.1) using fluorimetric and 
colorimetric enzyme assay kits, respectively. The peptide did not inhibit any of them up 
to 100 mol/L. Still, we cannot totally exclude the possibility that the peptide may 




Table 1. Compilation of the information about the enzymes that have the ability to degrade enkephalins. The information below was compiled from http://www.sigmaaldrich.com/technical-
documents/articles/biology/rbi-handbook/peptide-receptors-and-peptide-metabolism/neuropeptidases.html and the databases IUBMB, BRENDA, EXPASY, MEROPS, Wikigenes and NCBI.  
Abbreviations: AI – Angiotensin I, AII – Angiotensin II, AIII – Angiotensin III, ANP – atrial natriuretic peptide, BK – bradykinin, CCK – cholecystokinin, EDTA – ethylenediaminetetraacetic acid, 
EGTA – ethylene glycol-bis(2-aminoethylether)-N,N,N’,N’-tetraacetic acid, ET-1 – endothelin-1, ET-2 – endothelin-2, ET-3 – endothelin-3, GEMSA – guanidinoethylmercaptosuccinic acid, LTA4 – 
leukotriene A4 hydrolase, MGTA – 2-mercaptomethyl-3-guanidinoethylthiopropanoic acid, NKA – neurokinin A, NKB – neurokinin B, NT – neurotensin, PC18 – 2-amino4-methylsulfonyl butane 
thiol, SP – substance P, SS – somatostatin. 










































































































































enkephalin, ANP, ET-1, 
ET-2, ET-3, CCK, NT, SS, 





         
Table continued… 























































Plasma membrane Soluble, secreted, 
Golgi 
Soluble, cytosolic Plasma 
membrane, 
soluble (plasma) 

















































Inflammation Pain Cardiovascular 
regulation, 
fertility, water 











































The second part of this study intended to explore the anti-inflammatory mechanism of 
KTP-NH2 and to find a molecular link that could explain the multiple biological activities 
of the peptide, such as anti-inflammatory, analgesic and neuroprotective activities. We 
worked with a murine model of inflammation induced by lipopolysaccharide (LPS) and 
by CXCL-1 to show that KTP-NH2 has a very fast (10 minutes) and therefore 
nongenomic anti-inflammatory mechanism that probably blocks the 
activation/expression of adhesion molecules on the endothelium. We used an IVM 
approach combined with pharmacological inhibitors to demonstrate that KTP-NH2 has 
dual action: a glucocorticoid (GC)-mediated action, which is dominant in full-fledged 
inflammation models, and a GC-independent mechanism, which is predominant in 
models in which leukocyte rolling is stimulated but inflammation is not totally 
developed. Overall, the results show that GCs might be the molecular link that explains 








































Pain is a huge social and economic problem. The current analgesics available have the 
disadvantage of having side effects and/or not being always efficient. In addition, 
analgesics have not undergone significant changes over the last sixty years. Thus, an 
increased interest has been directed towards analgesic peptides. The dipeptide KTP 
gathers an interesting and wide set of biological activities; over the last years several 
KTP analogues have been improved to allow a peripheral administration with the 
analgesic effect of a central administration (4.2 fold more potent than endogenous 
opioids). The aim of this thesis was to better understand the mechanism of action and 
targets of KTP-NH2, a peptide developed by us with an increased pharmacological 
value compared to KTP. However, since the pharmacodynamics and pharmacokinetics 
of KTP-NH2 are not optimal (see appendix 1), we aimed to improve the peptide by 
introducing minor changes in the chemical structure. 
In article 2, we designed several KTP-NH2 analogues by introducing minor changes in 
the chemical structure of KTP-NH2 such as D-amino acid residues and/or N-terminal 
methylation. By doing that, we aimed to improve the pharmacodynamics of KTP-NH2. 
We accessed the efficacy of KTP-NH2 analogues as analgesic and anti-inflammatory and 
correlated the data with their respective PR. The results showed that the methylated 
analogues (Figure 2) have a prolonged analgesic effect probably due to its high PR but 
is pro-inflammatory. On the other hand, KTP-NH2-DL (Figure 2) has not a significant 
analgesic effect, which is in accordance with its low PR, but is anti-inflammatory. These 
structure-activity correlations support the hypothesis that KTP-NH2, which is analgesic 
and has a low PR, might cross the BBB using transporters not fitted to translocate KTP-
NH2-DL. Methylated analogues, in turn, might cross the BBB by a non-saturable 
mechanism, such as passive diffusion. KTP-NH2 analogues are more stable in human 
serum, but KTP-NH2 still is a more interesting peptide from the drug development 
strategies perspective. Among the analogues tested, only KTP-NH2 gathers analgesic 
and anti-inflammatory activities. Pain and inflammation frequently coexist. “Pain is a 
hallmark of inflammation and inflammatory pain is a major clinical problem in many 
disorders” (Conceição et al. 2016). The gold standard for pain treatment, the opioids, 
have deleterious side effects. Therefore, having a single dipeptide capable of targeting 





Figure 2. A schematic view of how minor chemical modifications impact the activity of 
the dipeptide KTP. 
Previous studies carried by us have shown the antimicrobial (Ribeiro et al. 2012) and 
neuroprotective (Sa Santos et al. 2016) properties of KTP-NH2. In addition, KTP-NH2 is 
cheap to synthesize, is safe (Ribeiro et al. 2013) and its physiological effects are well 
characterized in vivo. But in contrast with the abundant data on the biological action of 
KTP-NH2, its mechanism of action still is poorly understood. In article 3, we excluded 
the hypothesis that KTP-NH2 could be a generic inhibitor of enkephalinases as two 
model enzymes, ACE and DPP3, are not inhibited at therapeutic doses. However, the 
central hypothesis in article 3 was that the anti-inflammatory action could be the key 
to link analgesia and neuroprotection. So, we attempted to unravel the anti-
inflammatory mechanism of action of KTP-NH2 at the molecular level using 
pharmacological inhibitors. Using two models of inflammation, one induced with LPS 
and other induced with CXCL-1, we demonstrated that KTP-NH2 is able to decrease 
inflammation in both models in only ten minutes. In the full-fledge inflammation 
model induced with LPS, GCs were crucial to decrease inflammation and heme-
oxygenase 1 (HO-1) and interleukin-10 (IL-10) seemed to play a partial role in this 
process. Interestingly, in the model where the recruitment of neutrophils is induced by 


















we concluded that KTP-NH2 has dual action: a GC-mediated action, which is dominant 
in full-fledged inflammation models, and a GC-independent mechanism, which is 
predominant in models in which leukocyte rolling is stimulated but inflammation is not 
totally developed. Whichever the mechanism of action, it does not require de novo 
transcription. 
We have shown that KTP-NH2 and its analogues have an impact in the endothelium 
(section 2), which in turn play important roles in pain, inflammatory and 
neurodegenerative processes. For instance, there is increasing evidence that AD is a 
vascular disease with neurodegenerative consequences rather than a 
neurodegenerative disorder with vascular consequences.  
GCs regulate different aspects of endothelial physiology, such as the expression of 
adhesion molecules, production of cytokines and chemokines and maintenance of 
endothelial barrier integrity (Zielińska et al. 2016). We believe that GCs might be the 
molecular link to explain the main biological activities of the peptide since they 
regulate numerous homeostatic functions. In clinical setting, GCs are widely used as 
anti-inflammatory agents. Similar to KTP-NH2, GCs can also have naloxone-reversible 
analgesic effects (Kesmati et al. 2010). On the other hand, inhibition of GC receptor 
(GR) prevents the analgesic action of morphine, indicating a clear overlapping between 
the two pain modulation systems (Kesmati et al. 2010). 
It was recently reported that KTP-NH2 binds/perturbs LPS micelles, which would 
ultimately jeopardize signal transduction triggered by the binding of LPS to its 
receptor, TLR4. This was the mechanism proposed by Conceição and co-workers to 
explain the ability of KTP-NH2 to decrease the number of rolling leukocytes in a murine 
model of inflammation induced by LPS (Conceição et al. 2016). However, our findings 
weaken this hypothesis and suggest that KTP-NH2 anti-inflammatory mechanism is not 
primarily dependent of its interaction with LPS neither with TLR4 signaling pathway. It 
has rather a more general and unspecific mechanism such as blocking the 
activation/expression of adhesion molecules on the endothelium. 
In conclusion, the data presented in this thesis reinforces that KTP-NH2 is a 




is quickly metabolized (see appendix 1), our data support the hypothesis that KTP-NH2 
crosses BBB mediated by a saturable transport mechanism. The fast action of the 
peptide, within 10-15 minutes, either at peripheral or central level, points towards a 
nongenomic mechanism and the involvement of GCs might be the molecular link to 
explain the analgesic and anti-inflammatory properties of the peptide. This finding 
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The limited potential of KTP to induce analgesia after systemic administration (Chen et 
al. 1998), probably due to its inability to cross the BBB and/or susceptibility to 
enzymatic degradation, has stimulated the development of more efficient analogues. 
We have successfully designed KTP analogues applying strategies of conjugation with 
lipophilic groups (Ribeiro et al. 2011; Ribeiro et al. 2011), improvement of cationicity 
(Ribeiro et al. 2011), use of D-amino acids and substitution of peptide bonds (Serrano 
et al. 2015). KTP-NH2 is one of the successful analogues designed by us that retain the 
analgesic activity after systemic administration (Ribeiro et al. 2011). In 2011, KTP-NH2 
was patented (Ribeiro et al. 2009) for the treatment of pain recognizing its huge 
pharmacological potential. In addition, anti-inflammatory (Conceição et al. 2016) and 
neuroprotective (Sá Santos et al. 2016) properties have been described for KTP-NH2. 
As part of the pharmacological development of a drug, it is important to know its 
biodistribution/metabolism in vivo. In line with this context, in the following paper we have 
synthesized a radioioditanated KTP-NH2 analogue ([I
125]MIK) as a tool to evaluate KTP-NH2 
biological fate in vivo and to assess its ability to cross BBB. It turned out the [I125]MIK showed 
improved pharmacological properties over KTP-NH2. While KTP-NH2 is quickly metabolized by 
enzymes, [I125]MIK is moderately stable in human serum at 37°C. Moreover, [I125]MIK analgesic 
activity peaks later than KTP-NH2 (30 vs. 15 min, respectively) but the overall effect lasts for a 
longer period. This analgesic activity shows a good correlation with ability of the peptide to 
translocate lipid membranes in vitro, but only a very low percentage of [I125]MIK was found in 
the brain after systemic administration. Hereupon, we cannot exclude the peripheral effects of 
the radioiodinated peptide. The relative high levels of radioactivity found in the liver and 
intestines suggest that [I125]MIK is mainly removed by the hepatobiliary tract and probably 
undergoes enzymatic dehalogenation in the liver. The resulting free radioiodade is probably 
captured by the thyroid which presents relevant levels of radioactivity. Low levels of 
radioactivity in the blood reflect the rapid radiopeptide clearance. Nevertheless 72.5% of the 
radioactivity of the plasma collected 5 min post-injection corresponded to [I125]MIK. 
Labeling of such a small peptide as KTP-NH2 is challenging and the use of radioactivity seems to 
be the only approach that works in these cases. However, the strategy used in this article was 
not ideal since the designed radioiodinated analogue is not directly comparable to KTP-NH2. 
Future studies using radioactive atoms incorporated in the backbone of the peptide, such as 
tritium, will certainly improve our technique to follow the dipeptide in vivo. Nevertheless, this 
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article have shown the pharmacokynetics of the peptide is not optimal and must be improved 























































































Endothelium-mediated action of analog derivatives of the 
endogenous neuropeptide kyotorphin (Tyrosil-arginine): 
Mechanistic insights from permeation and effects on 
microcirculation. 
Juliana Perazzo§, Mônica Lopes-Ferreira†, Sónia Sá Santos§, Isa Serrano§, Antónia Pinto§, Carla Lima†, 
Eduard Bardaji‡, Isaura Tavares#, Montserrat Heras‡, Kátia Conceiçãoϕ*, Miguel A. R. B. Castanho§*. 
§- Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Av. Professor 
Egas Moniz, 1649-028 Lisboa, Portugal; 
†- Unidade de Imunorregulação, Laboratório Especial de Toxinologia Aplicada, Instituto Butantan, Av. 
Vital Brasil 1500 São Paulo, Brazil;  
‡- Laboratori d’Innovació en processos i Productes de Síntesi Orgànica (LIPPSO), Department de 
Química, Universitat de Girona, Campus Montilivi, 17071 Girona, Spain. 
#- Instituto de Biologia Molecular e Celular, Porto, Portugal; i3S - Instituto de Inovação e Investigação 
em Saúde, Universidade do Porto, Porto, Portugal; Departamento de Biologia Experimental, Faculdade de 
Medicina, Universidade do Porto, Portugal. 
ϕ- Departamento de Ciências e Tecnologia, Universidade Federal de São Paulo, UNIFESP, Rua Talim, 
330, São José dos Campos, Brazil. 
 
Table of contents 
 
1H-NMR (400 MHz, D2O) of KTP-NH2-DD S3 
HPLC of KTP-NH2-DD S3 
1H-NMR (400 MHz, D2O) of KTP-NH2-LD S4 
HPLC of KTP-NH2-LD S4 
1H-NMR (400 MHz, DMSO-d6 + a drop D2O) of Boc-D-Tyr(Bzl)-Arg-NH2 S5 
13C-NMR (100 MHz, DMSO-d6) and dept experiment of Boc-D-Tyr(Bzl)-Arg-NH2 S5 
HRMS (ESI) of Boc-D-Tyr(Bzl)-Arg-NH2 S6 
1H-NMR (400 MHz, D2O) of KTP-NH2-DL S6 
COSY experiment of KTP-NH2-DL S7 
13C-NMR (100 MHz, D2O) and dept experiment of KTP-NH2-DL S7 
HRMS (ESI) of KTP-NH2-DL S8 























1H-NMR (400 MHz, DMSO-d6, 110 ºC) of Boc-N-Me-Tyr(Bzl)-D-Arg-NH2 S9 
13C-NMR (100 MHz, DMSO-d6, 80 ºC) dept experiment of Boc-N-Me-Tyr(Bzl)-D-Arg-NH2 S9 
HRMS (ESI) of Boc-N-Me-Tyr(Bzl)-D-Arg-NH2 S10 
1H-NMR (400 MHz, D2O) of Me-KTP-NH2-LD S10 
COSY experiment of Me-KTP-NH2-LD S11 
13C-NMR (100 MHz, D2O) and dept experiment of Me-KTP-NH2-LD S11 
HRMS (ESI) of Me-KTP-NH2-LD S12 
HPLC of Me-KTP-NH2-LD S12 
1H-NMR (400 MHz, DMSO-d6, 80 ºC) of Boc-N-Me-Tyr(Bzl)- Arg-NH2 S13 
13C-NMR (100 MHz, DMSO-d6, 80 ºC) dept experiment of Boc-N-Me-Tyr(Bzl)-Arg-NH2 S13 
HRMS (ESI) of Boc-N-Me-Tyr(Bzl)-Arg-NH2 S14 
1H-NMR (400 MHz, D2O) of Me-KTP-NH2 S14 
COSY experiment of Me-KTP-NH2 S15 
13C-NMR (100 MHz, D2O) and dept experiment of Me- KTP-NH2 S15 
HRMS (ESI) of Me- KTP-NH2 S16 
HPLC of Me- KTP-NH2 S16 










1H-NMR (400 MHz, D2O) of KTP-NH2-DD 
 
 



















1H-NMR (400 MHz, D2O) of KTP-NH2-LD  
 
 


















1H-NMR (400 MHz, DMSO-d6 + a drop D2O) of Boc-D-Tyr(Bzl)-Arg-NH2 
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COSY experiment of KTP-NH2-DL 
 
 

















































1H-NMR (400 MHz, DMSO-d6, 110 ºC) of Boc-N-Me-Tyr(Bzl)-D-Arg-NH2 
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COSY experiment of Me-KTP-NH2-LD 
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Measure of relative permeability in permeation studies  
 
Relative permeability was measured using the transwell setup and data analysis methodology 
described in references S1 and S2. 
Relative permeability was calculated by dividing the slope of the kinetics of the Tyr residues 
fluorescence intensity in the apical compartment in lipid-covered filters by the same measurement 
in lipid-free filters, over a 10h period (Figure S1).  
 
  
Figure S1: Normalized fluorescence intensity plotted against time in lipid-covered (solid squares) 
and lipid-free filters (empty squares). Me-KTP-NH2 (A) and KTP-NH2-DL (B) are examples of 
highly and poorly permeable drugs, respectively. 
 
As shown in Table S1, means of PR ranged from 0.38 to 0.81. Comparing to KTP-NH2, the PR 
of Me-KTP-NH2-LL was significantly higher, whereas there were no significant differences with 
Me-KTP-NH2-LD, KTP-NH2-DL or KTP.  
 
Table S1: Relative permeability of Me-KTP-NH2, Me-KTP-NH2-LD, KTP-
NH2-DL, KTP, and KTP-NH2. Data showed as means ± SD; each group is an 
average of three independent measures. ***P < 0.001, and ns not significant, 
versus KTP-NH2. One-way ANOVA P < 0.0001, followed by Tukey’s post test.  
Kyotorphin derivatives Relative permeability (PR) 
Me-KTP-NH2 0.805±0.092 *** 
Me-KTP-NH2-LD 0.659±0.028 ns 
KTP 0.583±0.059  ns 
KTP-NH2 0.489±0.060  
KTP-NH2-DL 0.377±0.065 ns 
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